HER2 drug
OS Therapies Refiles IPO for $6M to Fund Phase 2 HER2 Drug and Preclinical ADCs
OS Therapies, IPO, HER2 drug, preclinical ADCs, immunotherapy, NYSE American exchange
Actionable Insights Powered by AI
OS Therapies, IPO, HER2 drug, preclinical ADCs, immunotherapy, NYSE American exchange